Table 4.
Incidence of Hepatocellular Carcinoma (%) After Liver Biopsy in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease
| Marker | Category | Number of patients (%) | 1 y | 3 y | 5 y | 10 y | 15 y |
|---|---|---|---|---|---|---|---|
| aMAP score | 0–50 | 37 (17.1) | 0 | 0 | 0 | 0 | 0 |
| 50–60 | 107 (49.3) | 0 | 2.3 | 4.3 | 13.5 | 22.2 | |
| 60–100 | 73 (33.6) | 0 | 5.1 | 11.4 | 39.7 | 49.7 | |
| FIB-4 index | <1.30 | 14 (6.4) | 0 | 0 | 0 | 0 | 0 |
| 1.30–2.67 | 70 (32.0) | 0 | 1.7 | 1.7 | 1.7 | 21.4 | |
| >2.67 | 135 (61.6) | 0 | 3.6 | 8.3 | 29.9 | 34.6 | |
| ALBI score | ≤ −2.60 | 141 (65.3) | 0 | 4.2 | 5.8 | 16.1 | 16.1 |
| > −2.60 | 75 (34.7) | 0 | 0 | 6.1 | 24.1 | 50.2 |
Patients With F3, F4 Liver Fibrosis (n = 219).